PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Bio3 Research Srl

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Bio3 Research Srl and ProtElix, Inc. Enter into an Agreement for the Development of Mimic-antibody - Bio3 Research S.r.l. and ProtElix Inc. enter into an agreement for the development of mimic-antibody HMGB1 antagonists to prevent restenosis and atherosclerotic plaque progression - Bio3Research.com
Bio3 Research Srl and ProtElix, Inc. Enter into an Agreement for the Development of Mimic-antibody

 

NewswireToday - /newswire/ - Milano, Italy, 2008/09/17 - Bio3 Research S.r.l. and ProtElix Inc. enter into an agreement for the development of mimic-antibody HMGB1 antagonists to prevent restenosis and atherosclerotic plaque progression - Bio3Research.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Bio3 Research S.r.l. and ProtElix, Inc. announced today that they have entered into a non-exclusive worldwide collaboration for the development and commercial exploitation of mimic-antibody HMGB1 antagonists to prevent restenosis and atherosclerotic plaque progression. Anti-HMGB1 mimic-Abs will be generated by ProtElix using its proprietary technology platform and under a non-exclusive license to utilize Bio3 Research’s patent (IP WO02074437) relating to HMGB1 for cardiovascular disorders. Patents have been granted to Bio3 Research in Italy and Australia and the patent nationalization phase is underway in the USA, EU, Japan, Canada, China and Mexico.
Through a licensing program, Bio3 Research and ProtElix will jointly carry out the commercial exploitation of the mimic-Abs in key pharmaceutical markets. No details on commercial terms have been disclosed.

Dr Roberto Crea, Chairman and CEO of Protelix Inc., commented, “The collaboration with Bio3 Research is a great opportunity for ProtElix to direct its proprietary antibody mimics platform to important applications in cardiovascular diseases and cancer. We are very pleased to combine Bio3 Research’s Intellectual Property and marketing expertise with our “core” technology to discover and develop cheaper and more effective protein drug antagonists”.

Mr. Francesco Paolo Pilato, President and Chief Executive Officer of Bio3 Research commented: “Mimic-Abs represent an innovative approach to antagonizing HMGB1, a biological target recognized as one of the major factors contributing to several cardiovascular disorders. The world market potential for therapeutics in this area is in the range of $35 Billion. Bio3 Research has already focused on the possible development of monoclonal antibodies to antagonize HMGB1. By developing an HMGB1-specific mimic-antibody using ProtElix’s pioneering technology, we may accelerate the development of new therapeutic tools with better tissue penetration, the potential for non-injected formulations, higher stability, lower production costs and longer shelf-life.

ProtElix Inc. is a biotech R&D company located in Hayward, CA, USA. The Company was founded in 2006 by Dr. Roberto Crea, a serial entrepreneur in the biotech industry, as result of the sale of Bioren, Inc. to Pfizer in 2005. While Pfizer has acquired the worldwide exclusive rights to protein engineering technology for applications in the antibody space, ProtElix has retained the rights to the same platform technology for all other class of protein therapeutics. The Company has focused its initial technology applications on protein antagonists and enzyme engineering.

Bio3 Research S.r.l. is a biopharmaceutical company with its corporate headquarters in Milan, Italy and a subsidiary, Bio3 Research Inc., based in Hayward CA, USA. The company is engaged in several development projects, including the use of HMGB1 in connective tissue regeneration and the prevention of severe anemia in hemodialyzed patients with its proprietary therapeutic agent Biocysan™, already licensed to Daxley Group in Latin America and Mexico.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Bio3 Research Srl

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Bio3 Research Srl and ProtElix, Inc. Enter into an Agreement for the Development of Mimic-antibody

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Federico Gardini - Bio3Research.com 
f.gardini[.]bio3research.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Bio3 Research Srl securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Bio3 Research Srl / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  BizJobs.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)